Up next

Autoplay

Managing Bone Health in Metastatic Breast Cancer

2 Views • 07/03/23
Share
Embed
administrator
administrator
Subscribers
0

Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay